Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma

Kajino, T.; Higuchi, M.; Hata, K.; Shibata, N.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(1): 115-117

1996


ISSN/ISBN: 0385-0684
PMID: 8546461
Document Number: 457764
Combination chemotherapy with irinotecan and CBDCA was performed for two patients in the terminal stage of ovarian carcinoma. Every week, 75 mg.m-2 of irinotecan and 75-100 mg.m-2 of CBD CA were intravenously administered. Both patients showed a partial response. Diarrhea was not a characteristic side effect of irinotecan in this case. Dose limiting factors were leucopenia and thrombocytopenia.

Document emailed within 1 workday
Secure & encrypted payments